Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Acromegaly

Endocrine & Hormonal

Acromegaly Clinical Trials and Treatments

Also called Growth Hormone Excess, Gigantism (pediatric form)

Acromegaly results from chronic growth hormone excess, most commonly from a growth hormone-secreting pituitary adenoma. Elevated growth hormone stimulates insulin-like growth factor 1 (IGF-1) production, which mediates most systemic effects.

In plain words, acromegaly is a rare hormone disorder where the body makes too much growth hormone, usually from a growth on the pituitary gland. Over many years the hands, feet and face slowly grow larger, and problems like heart disease and diabetes can follow.

Get an email when new Acromegaly trials open or the FDA decides. Get alerts

Acromegaly

Where treatments stand, from ClinicalTrials.gov and FDA labels

Open and active trials18
Recruiting now13
Phase 1 · first safety tests2
Phase 2 · does it work1
Phase 3 · studies for approval3

Also 12 studies with no phase, like observational studies.

FDA review1

Oclaiz, Dec 18, 2026

FDA-approved medicines7

Mycapssa · Palsonify · Sandostatin · Signifor LAR · Somatuline Depot · 2 more

Acromegaly has 7 FDA-approved medicines, 18 open or active clinical trials (13 recruiting), and a pending FDA decision on Oclaiz, due Dec 18, 2026.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Acromegaly

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Acromegaly

The gradual onset makes early recognition difficult. Characteristic features include progressive growth of hands and feet, coarsening of facial features with prognathism (jaw protrusion), increased nose size, lip thickening, and increased spacing between teeth.

Keep reading about Acromegaly

Systemic complications are serious. NORD reports high blood pressure in about 25% of people with acromegaly, and NIDDK lists type 2 diabetes, heart disease, sleep apnea from soft tissue overgrowth in the airway, arthritis and carpal tunnel syndrome. Cancer risk is modestly higher, particularly for colon and thyroid cancer. Neurologic complications can result from mass effect of the adenoma, including vision loss from optic chiasm compression and headaches.

Diagnosis rests on a high IGF-1 level for age in someone with typical features. When results are borderline, a glucose tolerance test checks whether growth hormone fails to fall, according to a 2024 expert consensus. Untreated, acromegaly can lead to early death, and with successful treatment life expectancy may return to normal, according to NIDDK.

Patients described what living with acromegaly is like at the only patient-focused drug development meeting on acromegaly listed by the FDA, held by Acromegaly Community in January 2021. In polls of people with acromegaly at that meeting, 92% reported fatigue or muscle weakness and 90% joint problems or arthritis, and these were the 2 symptoms most often ranked among the most troublesome. A main theme of the meeting was that symptoms often continue even when growth hormone and IGF-1 tests come back normal, so a normal lab result does not always mean a person feels well.

What are the symptoms of Acromegaly?

These are common symptoms of Acromegaly, and how strong they are varies from person to person.

  • Enlarged hands and feet requiring larger shoe and glove sizes
  • Coarse facial features with enlarged nose, lips, and forehead
  • Sleep apnea and snoring from soft tissue overgrowth in the airway
  • Persistent headaches from pituitary tumor pressure
  • Joint pain and arthritis
  • Excessive sweating, skin tags, and fatigue
  • Vision changes or loss of peripheral vision from optic nerve compression
  • Carpal tunnel syndrome with numbness and tingling
  • Increased spacing between teeth and jaw protrusion
  • Deepening of the voice

Who gets Acromegaly?

Acromegaly most often appears in people in their 30s and 40s, according to NORD, though it can start at any age after puberty. Before puberty, the same growth hormone excess causes gigantism. It affects males and females equally.

Most cases (90-95%) result from a pituitary adenoma secreting growth hormone. Less commonly, ectopic growth hormone-releasing hormone (GHRH) or growth hormone production from non-pituitary tumors occurs.

Next steps: find trials you might fitcompare treatmentsget help payingget alerts

Which medicines are FDA-approved for Acromegaly?

There are currently 7 FDA-approved medications for Acromegaly.

Side by sideCompare the 6 main acromegaly medicines side by sideHow each of the medicines is taken, what the trials showed and the warnings on the label, in plain language.Open the comparison
Just prescribed one of these?Your first 90 days, step by stepWhat happens before the first fill, the tests and refills to expect, and help paying, with a one-page handout to print.
PalsonifySandostatin LAR DepotSomatuline Depot
octreotide (oral capsules)
Chiesi (originally Chiasma)
Search
paltusotine
Your first 90 days
Vertex Pharmaceuticals (acquired Crinetics Pharmaceuticals, September 2026)
Search
octreotide
Your first 90 days
pasireotide
Recordati Rare Diseases
Official site
lanreotide
Your first 90 days
pegvisomant
Parlodel
bromocriptine mesylate

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Which new Acromegaly medicines are in trials?

Investigational medicines Trial Friend tracks for Acromegaly, with trial results, safety findings and where each one stands.

Oclaiz (octreotide (subcutaneous depot))Phase 3
Somatostatin analog (long-acting depot) · Camurus

How to get help paying for Acromegaly treatment

Charity funds and drugmaker programs for Acromegaly, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · TotalAssist (formerly PAN Foundation)
    Acromegaly fund
    Open

    Pays for: Out-of-pocket costs for approved medications, up to $5,000 per year. Requires Medicare, Medicaid or TRICARE.

  • From a charity · The Assistance Fund
    Acromegaly fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on October 26, 2026.

Every program and fund for Acromegaly, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Acromegaly

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Acromegaly resources

Reputable organizations and medical references for learning more about Acromegaly, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Acromegaly

Use this Acromegaly clinical trial finder to see the 13 studies recruiting patients and 5 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 8 test a treatment and 10 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

FDA decision ahead: Oclaiz (octreotide subcutaneous depot), due December 18, 2026. All upcoming decisions

Jump to the trial list, the site map, the pipeline timeline or the medication checker.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

18 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 1Recently updatedNCT07909837

A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy Volunteers

Intervention: NTQ6179, NTQ6179 placebo

Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical

This is a phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of single oral doses of NTQ6179 tablets in healthy participants. A total of 56 healthy participants wil...

Ages 18 Years to 55 Years1 location
Started Apr 2026Updated 1 week agoEst. Apr 2027 (~5 months)
RecruitingObservational study, no treatment givenRecently updatedNCT07583563

An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly

Intervention: Octreotide subcutaneous depot

Sponsor: Camurus AB

The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.

Ages 18 Years+
Started Jun 2026Updated 2 weeks agoEst. Jun 2029 (~2y 7m)
RecruitingTreatment trialPhase 3Recently updatedNCT06930625

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

Intervention: Debio 4126, Placebo

Sponsor: Debiopharm International SA

The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.

Ages 18 Years+
Started Nov 2025Updated 3 weeks agoEst. Jun 2028 (~1y 7m)
RecruitingObservational study, no treatment givenRecently updatedNCT00001595

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

Intervention: Tissue specimen collection, MRI

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood. The gene(s) involved in the pathogenesis of these tumors are largely not known; thei...

Ages 2 Years to 70 Years1 location
Started Apr 1997Updated 3 weeks agoCompletion date not listed
RecruitingTreatment trialRecently updatedNCT07866846

Managing Pasireotide-associated Hyperglycaemia in Acromegaly With Ketogenic Diet

Intervention: Ketogenic diet, Diabetes Medication

Sponsor: Leiden University Medical Center

Rationale: Pasireotide is a second line medical treatment for acromegaly that can add value for patients with insufficient control of disease on 1st generation SRL, or 1st generation SRL + pegvisomant. A well-known advserse effect of pasireotide is development of hyperglycemia in...

Ages 18 Years+1 location
Started Jul 2025Updated 1 month agoEst. Dec 2027 (~1y 1m)
Find Acromegaly trials near you, ranked by distance →
Active trial locations14 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+6 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Phase 3
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Acromegaly trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run an Acromegaly foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Can I Join an Acromegaly Clinical Trial While Taking My Current Medications?

This medication conflict checker helps acromegaly patients find out if their current medications could affect clinical trial eligibility. Select one or more medications below to instantly screen active trials for potential conflicts.

Acromegaly treatment often involves multiple medications working together: a somatostatin analog to lower growth hormone, possibly pegvisomant or a dopamine agonist as add-on therapy, plus medications for the comorbidities that come with the disease like diabetes, hypertension, and joint pain. Each clinical trial publishes eligibility criteria that may exclude specific drugs or drug classes, and these vary significantly from trial to trial.

How medications affect trial eligibility for Acromegaly
Somatostatin Receptor Drugs
Sandostatin LAR, Somatuline Depot, Signifor LAR, Mycapssa, Palsonify: trials testing new mechanisms of action frequently exclude patients on current SRL therapy or require a washout period of 3 to 6 months. Octreotide, lanreotide, pasireotide, oral octreotide, and paltusotine are the most commonly excluded drugs in acromegaly trials.
GH Receptor Antagonist
Somavert (pegvisomant): because pegvisomant normalizes IGF-1 through a different mechanism than SRLs, many trials exclude it to avoid confounding results. Washout periods of 8 weeks to 12 months are common. Some combination studies actually require patients to be on a stable SRL dose while excluding pegvisomant.
Dopamine Agonists
cabergoline (formerly sold as Dostinex), Parlodel (bromocriptine): used as adjunctive therapy in patients with mild IGF-1 elevation or co-secreting prolactin. Trials may exclude dopamine agonists or require a 4-week to 3-month washout. Shorter washout than SRLs due to faster clearance.
Comorbidity Medications
Diabetes, blood pressure, pain, and mood medications: acromegaly commonly causes blood sugar problems (about half of patients, according to NORD), high blood pressure (about 1 in 4), joint pain, and depression. These comorbidity medications are rarely the reason a trial excludes you. When they appear in eligibility criteria, the language usually says uncontrolled diabetes or unstable blood pressure rather than banning the medications outright.

If you take pasireotide (Signifor): a note about diabetes medications

Pasireotide raises blood sugar in most patients, and its label reports diabetes as a side effect in 21-31% of patients in its acromegaly trials, so many people on Signifor also take metformin, insulin, or other diabetes medications specifically because of their acromegaly treatment. If the checker flags your diabetes medication at low confidence, that's because the trial mentions diabetes or glucose in broad terms. It doesn't necessarily mean you're excluded. The study team will evaluate your specific situation, including whether your diabetes is medication-induced and well-controlled.

A conflict doesn't always mean you can't join

Many conflicts come with a washout period, meaning you may be able to participate if you stop the medication for a certain amount of time before the trial starts. For example, a trial might require stopping octreotide for 6 months or pegvisomant for 8 weeks. Whether a washout is safe and feasible depends on your disease activity and should always be discussed with your endocrinologist. The checker shows washout periods when the trial specifies them.

Had pituitary surgery? Your hormone replacements are usually allowed

Post-surgical patients often take hydrocortisone, levothyroxine, desmopressin, or sex hormones to replace what the pituitary gland no longer produces. Even when a trial excludes glucocorticoids or steroids, there is typically an exception for physiologic replacement doses. If the checker flags one of your replacement hormones, check the excerpt text carefully. You'll often see language like except physiologic replacement or stable hormone substitution permitted.

Don't see your medication listed?

The checker covers the medications most relevant to acromegaly patients, including acromegaly-specific treatments, diabetes medications, blood pressure medications, pain medications, psychiatric medications, thyroid replacement, and post-surgical hormone replacement. If your medication isn't in the list, that means we haven't found it commonly mentioned in acromegaly trial exclusion criteria. You should still tell the study team about all medications you take when you contact them.

How the medication conflict checker works: This free tool helps acromegaly patients learn if their current medications could affect clinical trial eligibility. It scans the published eligibility criteria of every active acromegaly clinical trial and flags which ones may exclude your specific treatment. Matches are categorized by confidence level: high confidence means the trial names your exact drug, medium confidence means it references your drug class, and low confidence means it uses broad category language that may or may not apply to you. Select one or more of your medications above to instantly see which trials you may still qualify for and which ones could be a problem. Always confirm eligibility directly with the study team, as final decisions involve your complete medical history, hormone levels, imaging, and your endocrinologist's assessment.

Across 1,853 open rare disease treatment trials, a third exclude people over a medication they commonly take. See which medications and diseases, in our September 2026 analysis.

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Acromegaly patient communities

Facebook groups, Reddit communities and YouTube channels where Acromegaly patients, caregivers and advocacy groups talk.

Acromegaly Community Inc.
Patient advocacy group that held the only FDA-listed patient-focused drug development meeting on acromegaly (January 2021), with 2,800+ patients and caregivers worldwide
Acromegaly Community on Facebook
Closed groups for patients, families, and caregivers
Acromegaly Community on YouTube
Conference recordings, patient education, and awareness videos
Pituitary World News
Acromegaly news, research updates, and patient stories since 2014
AcroTales Podcast
Interviews with acromegaly patients from around the world (iTunes, Spotify)
r/rarediseases · Acromegaly
Acromegaly posts and discussions
NORD Rare Disease Report
Reviewed plain-language medical overview from the National Organization for Rare Disorders, with assistance program listings
Growth Hormone and Pituitary Tumors
Growth Hormone and Pituitary Tumors
Mayo Clinic
Watch on YouTube

Acromegaly events

Free support groups where people with acromegaly and other pituitary tumors meet others who understand, and hear from pituitary specialists. The support groups can all be joined from home. One listing is a conference for doctors and other health professionals, not for patients, and is marked that way.

Pacific Neuroscience Institute
Pacific Neuroscience InstituteFrom pacificneuroscienceinstitute.org, checked October 17, 2026
Support Group

Pacific Neuroscience Institute Pituitary Support Group

When
12:15 to 1 PM Pacific2nd Thursday of every month
Where
Zoom
Cost
Free
For
Patients with a pituitary tumor or a growth near the pituitary

A monthly Zoom group for patients diagnosed with a pituitary tumor or another growth near the pituitary gland, which includes acromegaly. Members share their experiences and can ask questions of guest speakers, including healthcare professionals.

More about this event

The group is for patients only and meets from 12:15 to 1:00 PM Pacific time. Sign up through the online form on the institute's page to get the meeting link.

Add to Google Calendar
Brigitte Harris Cancer Pavilion, Henry Ford Cancer-Detroit
2800 West Grand BlvdDetroitMI48202US
Henry Ford Health
Henry Ford HealthFrom henryford.com, checked October 17, 2026
Support Group

Henry Ford Skull Base and Pituitary Support Group

When
5:30 to 7 PM Eastern
Where
Detroit, MI, or online
Cost
Free
For
People with a pituitary tumor and their loved ones

A support and education group for people with a pituitary tumor and their loved ones. Henry Ford physicians and staff run each meeting, and a guest speaker covers the latest information and research on pituitary disorders.

More about this event

You can attend in person in Detroit or join online. Each option has its own registration on Henry Ford's page, and online attendees get the link a few days before the meeting.

Add to Google Calendar
Barrow Neurological Institute
Barrow Neurological InstituteFrom barrowneuro.org, checked October 17, 2026
Acromegaly Group

Barrow Acromegaly Support Group

When
4 to 5 PM Arizona time4th Wednesday of the month, no meetings in November or December
Where
Zoom
Cost
Free
For
People living with acromegaly

This is the only group listed here that is just for acromegaly. People living with acromegaly meet on Zoom to share their stories, support each other and talk with Barrow's pituitary specialists.

More about this event

The group does not meet in November or December, so the next meeting by its monthly schedule is January 27, 2027, from 4 to 5 PM Arizona time. Barrow asks you to RSVP a week ahead to get the Zoom details.

Add to Google Calendar
Annenberg Community Beach House
Pacific Neuroscience Institute
Pacific Neuroscience InstituteFrom pituitary.org, checked October 17, 2026
For Doctors Only

2027 Neuro-Endocrine Pituitary Conference (for doctors)

When
8:30 AM to 3:45 PM Pacific
Where
Santa Monica, CA
For
Doctors and other health professionals, 5 CME credits

This is a medical education course for doctors and other health professionals, not a patient event. The organizers list the audience as endocrinologists, neurosurgeons, primary care physicians, nurse practitioners, physician assistants, fellows and residents, and the course offers 5 CME credits.

More about this event

Topics include hormone excess conditions like acromegaly, pituitary imaging, surgery decisions, care after surgery and long-term follow-up. If your doctor treats pituitary disease, this is a course you could mention to them.

Add to Google Calendar

Details come from each host's own page, checked October 17, 2026. Where a host lists a repeating schedule rather than dates, the dates shown here follow that schedule, so confirm the date and time when you register.

Acromegaly news and guides

Trial Friend articles about Acromegaly, newest first

Companies developing Acromegaly treatments

Drugmakers that list Acromegaly in their rare disease portfolio, 11 in all.

Crinetics Pharmaceuticals
Rare disease specialist · 4 rare diseases
Pfizer Inc.
Diversified pharma · 69 rare diseases
Novartis
Diversified pharma · 59 rare diseases
Chiesi Farmaceutici
Diversified pharma · 14 rare diseases
Recordati Rare Diseases
Diversified pharma · 12 rare diseases
Ipsen
Diversified pharma · 11 rare diseases
Camurus AB
Diversified pharma · 2 rare diseases
Alexion Pharmaceuticals
Rare disease specialist · 35 rare diseases
Vertex Pharmaceuticals
Rare disease specialist · 12 rare diseases
Ionis Pharmaceuticals
Diversified pharma · 20 rare diseases
Italfarmaco
Diversified pharma · 4 rare diseases

Questions people ask about Acromegaly